Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Consensus Target Price from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received a consensus rating of “Reduce” from the fifteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $214.00.

Several equities research analysts recently commented on the stock. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Finally, UBS Group upped their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $185.39 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 12-month low of $176.48 and a 12-month high of $275.00. The firm has a fifty day moving average of $193.84 and a 200-day moving average of $201.84. The firm has a market capitalization of $9.48 billion, a price-to-earnings ratio of 23.20, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the previous year, the business posted $2.72 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently added to or reduced their stakes in the stock. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International in the third quarter valued at about $32,000. Assetmark Inc. boosted its stake in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).